DANSAC-RCT: Fosaprepitant in patients with advanced cancer not receiving chemotherapy or irradiation; A multicenter, randomized, double-blind, placebo-controlled study.

Trial Profile

DANSAC-RCT: Fosaprepitant in patients with advanced cancer not receiving chemotherapy or irradiation; A multicenter, randomized, double-blind, placebo-controlled study.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Fosaprepitant (Primary)
  • Indications Nausea; Vomiting
  • Focus Therapeutic Use
  • Acronyms DANSAC-RCT
  • Most Recent Events

    • 08 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top